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CD27,  a  transmembrane  disulfide-linked  55-kD homo- 
dimer, belongs to the nerve growth factor-receptor family, 
a group of homologous molecules involved in lymphocyte 
differentiation  and selection. It is expressed on mature  thy- 
mocytes, peripheral  blood T cells, and a subpopulation of B 
cells. We investigated the expression of CD27 on malig- 
nant B cells representative  for a broad range of stages in 
physiologic antigen-independent  and -dependent B-cell  de- 
velopment. In normal lymphoid tissue CD27+ B cells were 
only found in the peripheral blood (29.8% f  10.8%.  n = 
13) and in germinal centers. With the exception of pro-B 
and the majority of pre-pre-B acute lymphocytic leukemias 
and of  myelomas, CD27 expression of variable intensity 
was detected on almost all immature and mature malig- 
D27 IS  A TRANSMEMBRANE disulfide-linked 55-  C  kD homodimer present on mature thymocytes, on the 
vast majority of both CD4’  and CD8+ peripheral blood T 
and on a subset of B  cell^.^.^ Activation of T cells via 
the TCR/CD3 complex results in upregulation of CD27 ex- 
pression on the cell membrane as well as in the release of a 
soluble 28- to 32-kD form of CD27 (sCD27). This sCD27, 
which has an extensiv structural homology to the 55-kD 
transmembrane  m~lecule,~~~  can also be detected in body 
fluids like plasma, urine, and spinal  At present the 
function of CD27 is not known. However, CD27 belongs to 
the nerve growth factor receptor (NGF-R) family,’ a num- 
ber of structural homologous molecules including the two 
TNF  receptors,lO-’*  the B-cell antigen CD40,I3 the lympho- 
cyte activation antigen CD30,I4 and FAS/APO- 1, a mole- 
cule expressed on a number of cell lines and on activated T 
and B cells.15  Very recently the ligand of CD27 has been 
identified.16 Its sequence suggests that it is a type 2 trans- 
membrane protein with similarities to three other homolo- 
gous ligands of the NGF-R family,” ie, tumor necrosis fac- 
tor-a (TNF-a) and TNF-P, and gp39, the ligand of CD40.” 
Members of the NGF-R family appear to  be involved in the 
selection of lymphoid cells. In vitro CD40 antibodies pre- 
vent apoptosis of germinal center B cells, indicating an im- 
portant role for the CD40-CD40 ligand pair in antigen-dri- 
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nant B cells tested. Moreover, using a sandwich enzyme- 
linked immunosorbent  assay we  could show the presence 
of sometimes very high (up to 6,000 U/mL; normal values 
<  190  U/mL) amounts of the soluble 28- to 32-kD  form of 
CD27 (sCD27) in the sera of patients  with B-cell malignan- 
cies. The highest levels of sCD27 were observed in pa- 
tients with chronic lymphocytic leukemia and low-grade 
non-Hodgkin’s  lymphomas.  Most  importantly,  both  in 
transversal and  longitudinal studies,  we found a strong 
correlation between sCD27 levels in the serum and tumor 
load,  indicating that  sCD27  can be used as a  disease- 
marker in patients  with acute and chronic B-cell malignan- 
cies. 
0 1993 by The American Society of Hematology. 
ven  B-cell  se1ecti0n.l~  Recently,  mutations in  the CD40 
ligand have been shown to be responsible for the hyper-IgM 
syndrome, illustrating the in vivo importance of CD40 in 
B-cell maturation.”  APO-I  might also have a function in 
the regulation of lymphocyte survival because cross-linking 
of APO-1 by an anti-APO-1  monoclonal antibody (MoAb) 
induces apopt~sis.’~  In view  of the structural homologies 
with these receptor-ligand pairs, CD27 and its ligand may 
also play a role in the regulation of differentiation and/or 
selection of lymphocyte populations. 
B-cell leukemias and lymphomas are useful for the study 
of  differentiation-stage-related  expression of antigens.  In 
this report we  describe the expression of CD27 on human 
malignant  B  cells.  Moreover,  we  show  that  very  high 
amounts of soluble CD27 are sometimes present in the sera 
of patients with B-cell  malignancies and the existence of a 
close correlation between sCD27 in serum and tumor load. 
MATERIALS  AND  METHODS 
Tissues.  Normal and pathologic lymphoid tissues were selected 
from the files of the Department of Pathology, Academic Medical 
Center, University of Amsterdam, The Netherlands.  Non-Hodg- 
kin’s  lymphomas  were classified according to the  International 
Working  Formulation  (WF).2’ Expression  of  T-  and  B-lineage 
markers was used for classification as T- or B-cell lymphomas. 
Preparation and separation ofcell suspensions.  Normal periph- 
eral blood mononuclear cells were obtained by Ficoll-Isopaque (Or- 
ganon Teknika Corp, Durham, UK) density gradient centrifuga- 
tion  (density  =  1.077  g/cm3) of  EDTA  blood  from  healthy 
volunteers. In some experiments we used purified normal tonsillar 
B cells. Freshly obtained normal tonsillar tissue was dissected free 
from surface epithelium and finely minced into a cell suspension. 
Mononuclear  cells were isolated by  Ficoll-Isopaque  density gra- 
dient centrifugation. Monocytes were removed  by plastic adher- 
ence (1 hour at 37°C in 10 cmz Petri dishes [Costar, Cambridge, 
MA]). T cells were depleted  using 2-aminoethyl-isothiouronium 
bromide-modified  sheep red blood cells (SRBCs). The purified B 
cells were then layered on a Percoll gradient (Pharmacia, Uppsala, 
Sweden) consisting of five density layers ( 1.085/1.077/1.067/1.056/ 
1.043 g/cm3) and centrifuged for  15 minutes,  1,200g at 4°C. The 
cells at the 1.043/ 1.056 interface (low-density cells) and the 1.077/ 
1  .OS5  interface (high-density cells) were used in the experiments. 
Similarly, suspensions of malignant mononuclear cells were pre- 
pared from peripheral blood. bone marrow (BM), or lymph node 
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Fig 1.  (A) Coexpression of CD19 and CD27 on 
peripheral blood lymphocytes.  (B) Lack  of coex- 
pression  of CD5 and CD27 on gated  CDl9+  periph- 
eral blood lymphocytes. Triple-labeling  with biotin- 
ylated  CD1  S/Cy-chrome  labeled  streptavidine, 
CD5-PE,  and CD27-FITC was  performed as de- 
scribed in Materials and Methods. CD27 expres- 
sion on  tonsil B cells: High (C) and low  (D) density B 
cells  were isolated  from tonsil  tissue and double-la- 
beled with anti-CD27 and PNA-FITC as described 
in Materials and Methods. 
CDlWCb27  I 
Fig 2.  Expression of  CD27 on normal tonsil lymphocytes and B-cell NHLs. (A) Section of tonsil showing strong expression of CD27 in 
interfollicular T-cell areas (T). Mantle zone (M) B cells are CD27- whereas Germinal center (GC) B cells show a variable CD27 expression. 
(B) Higher magnification of tonsillar GC  showing variable expression of CD27 in GC  cells. (C) B-CLL lymph node showing strong CD27 
expression. (D) Burkitt's lymphoma showing weak CD27 expression. Counterstain hematoxylin. Bar: (A) 250 pM; (B through D) 100 rM. 
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Table 1.  Expression of CD27 in B-Lineage Leukemias 
Subtype  Posflotal  MFI'  (range) 
Pro-B ALL 
Pre-preB-  ALL 
PreB-ALL 
B-ALL 
CLL 
PLL 
HCL 
My  e  lo  in a 
- 
250-320 
450/300 
600/550 
450-800 
5001485 
4 10-600 
- 
* Median fluorescence intensity (linear scale). 
biopsies of patients with B-cell malignancies. For the studies on the 
expression of CD27 on B-cell precursors we used normal BM aspi- 
rated  from patients undergoing cardiac surgery or from patients 
with lymphoma whose BM was obtained for clinical staging and 
was found to be  free from disease. BM  mononuclear  cells were 
isolated by Ficoll-Isopaque density gradient centrifugation. 
Informed consent from patients and healthy volunteers was ob- 
tained according to the rules of our hospital. 
Immunocytology.  The phenotype of the cell suspensions was 
determined by  fluorescence-activated cell sorter (FACS) analysis 
using the following MoAbs in an indirect immunofluorescence tech- 
nique: CLB-CD313, CLB-CD41  I, CLB-CD5, CLB-CD8/4, CLB- 
CD  10,  CLB-CD 19, CLB-CD20, CLB-Blast-2(CD23), CLB-CD24, 
CLB-IL2R/I(CD25),  CLB-CD27/1,  anti-IgM(MH 15),  anti- 
IgG(MH 16), all produced at the Central Laboratory of the Nether- 
lands Red Cross Blood Transfusion Service, Amsterdam, and clus- 
tered in the international workshops on leukocyte differentiation 
antigens. Anti-K, anti-A, anti-IgD, and CD22 were purchased from 
DAKO (Glostrup, Denmark). Binding of the antibodies was visual- 
ized  with  fluorescein  isothiocyanate  (F1TC)-labeled poloclonal 
goat-antimouse IgG (GAM). In some double-labeling experiments 
we  used CDI 9-phycoerythrine (PE) from Becton Dickinson (BD; 
Sunnyvale, CA). To block free binding sites on GAM antibodies, 
cells were incubated with normal mouse serum and washed before 
addition of CD19-PE. In studies with the purified tonsillar B cells 
we  used goat-antimouse-PE  (Southern Biotech. Assoc. Inc, Bir- 
mingham, AL) and PNA-FITC (Sigma, St Louis, MO). In the tri- 
ple-labeling experiments peripheral blood mononuclear cells were 
incubated with CD27-FITC (CLB), CD5-PE (BD), and biotinylated 
CD  19 (CLB). After washing, Cychrome-labeled streptavidine (ITK 
Diagnostics, Uithoorn, The Netherlands) was added. In the triple- 
labeling experiments with BM mononuclear cells we used two dif- 
ferent combinations of MoAbs during the first incubation step: (I) 
CD34-FITC (CLB), CD19-PE (BD), and biotinylated CD27 (CLB); 
(2) CDIO-PE (BD), biotinylated  CD19 (CLB), and CD27-FITC 
(CLB). PERCP-labeled streptavidine (BD) was added after washing. 
Table 2.  Expression of CD27 in B-Lineage NHLs 
n 
~  +/-  t  +t 
Diffuse small cell  6  0  0  1  5 
Follicular  7  0  2  2  3 
Diffuse large cell  9  1  2  4  2 
lmmunoblastic  6  0  2  2  2 
Burkitt  6  1  2  2  1 
CD27 expression  was analyzed by immunoperoxide staining of cryo- 
stat sections. The intensity of the reaction was scored with CD27 ex- 
pression on T cells (++)  as a reference (see also Fig 2,  C and D). 
Abbreviations: -, negative, +I-,  very weak/equivocal; +, weak; ++, 
moderate/strong. 
Low-grade 
Intermed./high grade 
s-CD27 
Wml) 
10000 r 
3000 - 
1000  r 
300 - 
30  1 
.  .  .  .  . 
0.. .  .  .  . 
.  0.. .  .  .  . 
Normal  ALL  CLL  NHL  MM 
Fig 3.  Levels of soluble CD27 (sCD27) in sera from healthy con- 
trols (normal, n = 43). ALL (n = 4). CLL (n = 411, NHL (n = 65). 
and multiple myeloma (MM, n = 12). Dashed line indicates mean 
+ 3 SD of sCD27 in control group. 
Staining with  irrelevant  isotype-matched  antibodies  was always 
used as control. 
Immirnohistochemistry.  Immunoperoxidase  staining was per- 
formed as described previously.22  In brief, cryostat sections were 
fixed in aceton for IO minutes, washed in phosphate-buffered saline 
(PBS), and preincubated  with normal goat serum (10% in PBS). 
After preincubation the sections were incubated with the primary 
antibody for I hour. Before incubating with the secondary biotiny- 
lated antibody for 30 minutes [antimouse and antirabbit  F(ab),, 
(DAKO  Glostrup,  Denmark)],  endogenous  peroxidases  were 
~4027 
Wml) 
10000 
3  000 
1000 I 
t 
300  ' 
100 
0: .. 
0.0 ..  ...  ..  .. 
0.' 
..  .. 
....  ...  ..  - - - -  - - -  ..  .. 
LOW  Intermediate  Hloh 
30 
Fig 4.  Serum levels of soluble CD27 (sCD27) in B-cell NHLs of 
low- (n = 31). intermediate- (n = 24), and high- (n = 13)  grade 
malignancy. Dashed line: mean + 3 SD of sCD27 serum levels in 
43 healthy controls. *P < .0001: **P < .0035. 
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lyzed for the simultaneous expression of CD19 and CD27. 
A double-positive population could easily be shown in all 
individuals tested. A representative example is shown in Fig 
IA. The CD27'  B cells constituted 29.8% f  10.8%  (n = 13) 
of all peripheral blood B cells. The CD19'  and CD19- pe- 
ripheral blood lymphocytes differed as to the amount of 
membrane-bound CD27 as measured by the median fluores- 
cence intensities: 337 k  26 versus 467 _+ 8, respectively (P  < 
.OOO 1). In triple-labeling  experiments CD27 was found to be 
confined to the CD19+CD5- B cells (n = 3) (Fig 1B). In 
histologic sections of normal tonsils CD27'  cells were abun- 
dantly present in the T-cell areas (Fig 2A). In contrast, signif- 
icant numbers of CD27'  B cells were  only found in the 
germinal center (Fig 2, A and B). Similar data were obtained 
in  lymph  nodes and spleen (not  shown). Restriction  of 
CD27 expression to the germinal center B cells in the sec- 
ondary lymphoid organs was also demonstrated in expen- 
ments with suspensions of purified normal tonsil B cells. 
These cells were separated into high- and low-density B cells 
and analyzed for expression of CD27 and peanut agglutinin 
(PNA). As shown in Fig  1 (C and D) the vast majority of 
CD27'  B cells were  found within the low-density PNA' 
cells. These cells were also CD19'  and I@-,  a phenotype 
consistent with follicular center cells (data not shown).  Fig 5.  Serum levels of soluble CD27 (sCD27) in patients with 
CLL in diRerent disease stages according to the RAJ  classification. 
Dashed line: mean + 3 SD of serum sCD27 in 43 healthy controls. 
*Rai 0  versus Rai 1 + 2: P < .0025. *%ai 1 + 2 versus Rai 3 + 4: 
P < .065 (not significant). 
blocked by  0.3% H,O,  in methanol. All antibodies were titrated to 
give optimal staining results. For detection, a streptavidine-biotin- 
peroxidase complex (DAKO) was used. After incubation for 30 
minutes the sections  were incubated in 3,3-amino-9-ethyl  carbazole 
(Sigma) for 10 to 20 minutes. 
Soluble CD27 enzyme-linked  immunosorbent assay  (ELISA). 
sCD27 serum levels were determined by  ELISA  using two CD27 
MoAbs  directed  against  nonoverlapping  epitopes  (sandwich 
ELISA), essentially as described before.7ss  CLB-CD27/ 1 and CLB- 
CD27/3 (both IgG2a) were purified from axites by protein A affin- 
ity chromatography. CLB-CD27/ 1  was biotinylated according to 
standard procedures. The ELISA was performed in 96-well plates 
(Maxisorb; Nunc, Roskilde, Denmark) precoated for 2 hours at 
37°C with 100 pL of CLB-CD27/3 (5 pg/mL) in PBS (pH 7.4). The 
concentration of sCD27 was expressed as units per milliliter, by 
reference to a standard curve obtained from absorbance values of 
serial dilutions of pooled plasma of  15 healthy blood donors. The 
amount of sCD27 in pooled plasma was arbitrarily set at 100 U/ 
mL. The lower detection limit of this assay is 2 U/mL. In initial 
experiments it was found that neither source (plasma v serum)  nor 
storage affected sCD27 levels. 
Because of  the  known  effect  of  renal  dysfunction on  serum 
sCD27 levels:  patients with a serum creatinin exceeding 100 pmol/ 
L were excluded from analysis. The sera tested were separated from 
the blood immediately after coagulation and stored at -30°C  until 
Statislical  analysis.  The sCD27 data  were  analyzed by  the 
Mann-Whitney U-test. 
USe. 
RESULTS 
Expression of  CD27 on normal B cells and their precur- 
sors.  To have a basis for comparison with the results ob- 
tained with malignant B cells, we studied the expression of 
CD27 on normal B cells and B-cell precursors. Peripheral 
blood lymphocytes from 13 healthy volunteers were ana- 
In wo  alnerent  patients With  a  B-cell  malignancy.  (A) Common 
ALL; (6)  low-grade B-cell NHL. CR, complete remission; PR, partial 
remission; CT. chemotherapy. 
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CD27 expression during early stages of B-cell develop- 
ment was studied by triple-labeling experiments on mono- 
nuclear cells prepared from aspirates of normal BM. In six 
separate  experiments  we  found  that  in  both  the 
CD34+CD19+  cell fraction and in the CD19+CD10+  cell 
fraction CD27 expression did not exceed background levels 
(data not shown), indicating that normal B-cell precursors 
up to and including pre-B cells do not have membrane- 
bound CD27. 
Expression of  CD27  on malignant B cells.  Malignant B 
cells representative  for several differentiation  stages were 
analyzed for the presence of membrane-bound CD27. The 
results are shown in Table  1. It can be seen that CD27 is 
already present on malignant B cells corresponding to the 
early stages of antigen-independent B-cell maturation. Al- 
though all four pro-B acute lymphocytic leukemia (ALL) 
(CD34+/CD  19+/CD  1  O-/TdT+) tested were CD27-, CD27 
was present  on 4 of  17 pre-pre-B ALL (CD19+/CD10+/ 
cIgM-/TdT+),  and  2  of  3  pre-B  ALL  (CDI9+/CD10+/ 
cIgM+/TdT+). The two  B-ALLs tested  (CD 19+/CD  1  Of/ 
mIgM+/TdT-) had a high expression of membrane-bound 
CD27. Variable, but in general moderate to strong, expres- 
sion was found on chronic lymphocytic leukemia (CLL) 
cells, prolymphocytic leukemia, and two of four hairy cell 
leukemias.  Immunohistochemical  analysis of  non-Hodg- 
kin's lymphomas (NHLs) showed a moderate to high ex- 
pression of CD27 in most low-grade diffuse and follicular 
lymphomas and a highly variable expression on interme- 
diate- and high-grade lymphomas (see Fig 2, C and D, and 
Table 2). Myeloma cells were found to lack membrane ex- 
pression of CD27 (n = 6). 
Serum levels of  soluble CD27  in patients with B-cell ma- 
lignancies.  By  means  of  an ELISA  sCD27 levels were 
measured  in sera from groups of untreated patients with 
Fig 7.  Longitudinal study of 
serum  soluble  CD27  (sCD27) 
levels in a patient with a villous 
splenic  lymphoma  (low-grade 
NHL). Between day  1 and day 
75 patient received 3 courses 
25  50  '  75  of  polychemotherapy resulting 
in only a moderate reduction in 
spleen size. 
different types  of B-cell  malignancies.  In  sera  from  43 
healthy controls the mean (+SD) level of sCD27 was 103.3 
k 28.8 U/mL. With the exception of multiple myeloma (n 
=  12), in 98  of the  110 B-cell  leukemia and lymphoma 
patients tested, sCD27 was above the mean + 3 SD (1 90 
U/mL) of the control group (Fig 3). However, striking dif- 
ferences were observed between different groups. Very high 
levels (up  to 6,000 U/mL) of sCD27 were found in sera from 
patients with CLL. In patients with NHLs serum sCD27 
concentrations in those with low-grade lymphomas were 
significantly higher than in those with  intermediate  and 
high-grade lymphomas (P  < .0001 and P  -=  .0035, respec- 
tively) (Fig 4).  sCD27 levels in low-grade NHL were not 
significantly different from those in CLL (P  = .42). In the 
few T-cell malignancies tested (3 ALL and 2 NHL), sCD27 
levels were only  moderately  increased: range 278 to 684 
U/mL. 
In CLL a correlation 
was found  between  stage  (Raj classification) and serum 
sCD27 (Fig 5). Similarly, within this group of patients there 
was a correlation between sCD27 and the absolute number 
of circulating lymphocytes (r  = .79; data not shown). The 
possible correlation between clinical stage and sCD27 could 
not be  investigated in NHL because the vast majority of 
patients in this series had NHL stage 3 or 4 (Ann Arbor). In 
five patients we had the opportunity to study sCD27 levels 
longitudinally. In all these patients (four with NHL and one 
with pre-pre B-ALL) CD27 serum levels matched clinical 
disease activity cq tumor load: increased levels at diagnosis 
and relapse and normal levels during remission. Two exam- 
ples are shown in Fig 6. A dramatic change in the levels of 
sCD27 could be observed in a patient with a villous splenic 
lymphoma who, only partially responding to chemother- 
apy, underwent a splenectomy. After removal of  the very 
sCD27 is  related to tumor load. 
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From CD27 IN  B-CELL  MALIGNANCIES  3435 
large spleen (weight approximately 4 kg) sCD27 almost nor- 
malized within 24  hours (Fig 7), reflecting not  only the 
amount of tumour reduction obtained but also indicating 
that sCD27 has a plasma half-life time of less than 8 hours. 
We studied only one patient with a T-cell malignancy longi- 
tudinally. In this T-ALL patient the sCD27 normalized rap- 
idly  during chemotherapy and remained so during com- 
plete remission (1.5 years) (data not shown). 
DISCUSSION 
The two key  observations in this study are: (1) mem- 
brane-bound CD27 is present on malignant B cells represen- 
tative of almost all stages of B-cell ontogeny, and (2) soluble 
CD27 can be detected in the serum of many patients with 
B-cell malignancies and can be used as a marker for tumor 
load. 
Initial studies suggested that the expression of CD27 was 
confined to a (major) subset of T lymphocytes and thymo- 
cytes.L,2  More recently CD27 was also shown to be present 
on a subpopulation of mature B cells3 and natural killer 
cells.23  Our finding that about 30% of the normal peripheral 
blood B cells are CD27'  is in close agreement with the data 
published by Maurer et al.3 In comparison with the periph- 
eral blood T lymphocytes, B cells have a somewhat weaker 
CD27  expression. In  normal  tonsils,  lymph  nodes,  and 
spleen we  could only show CD27'  B lymphocytes in the 
more apical zones of the germinal centers. In 1992, Maurer 
et a14 reported that only CD27+ B cells are able to secrete Ig 
after stimulation with mitogens, suggesting that in B cells 
CD27 expression is related to maturation stage.4  This would 
be analogous to the situation for the T-cell lineage, where 
CD27 expression is acquired at the stage of the mature thy- 
mocyte.','  Recent evidence indicates  that CD27- T cells rep- 
resent a subset of memory cells arising after prolonged anti- 
genic a ti mu la ti on.'^ In view of the putative roles of other 
members of  the NGF receptor family (CD40 and FAS/ 
APO- 1) in lymphocyte selection and maturati~n,'~,~~,~~,~~ 
the observation that CD27 expression is restricted to ger- 
minal  center B cells  and  a  subpopulation of  peripheral 
blood B cells makes it tempting to speculate that CD27 is 
involved in the selection of B lymphocytes. The recent iden- 
tification and cloning of the CD27 ligand16 will enable stud- 
ies on the role of  CD27 in proliferation, differentiation, 
and/or selection of normal and malignant B cells. 
An  important  question is whether the observed CD27 
expression on malignant B cells representing almost all of 
the stages of the antigen-independent and -dependent B-cell 
development is a reflection of its expression during normal 
B-cell ontogeny. This is probably not the case because we 
were unable to show CD27 expression on normal BM B-cell 
precursors  up to and including the pre-B cell stage. Aberrant 
CD27 expression on malignant B cells is also suggested by 
our data on CLL cells: these pathologic B cells are CD27+, 
whereas their supposed normal counterparts in the follicle 
mantle zone27  are CD27-. Likewise, in triple-labeling exper- 
iments we  found that CD5+ peripheral blood B cells are 
CD27-. Furthermore, cord blood B cells, containing a large 
proportion of CD5+ cells,28  have been reported to be CD27 
negati~e.~  The same argument holds for the observed (weak 
to moderate) CD27 expression on Burkitt's lymphoma cells 
and the absence of CD27 on their putative normal counter- 
parts in the germinal center basal dark ~one.~~,~'  The mecha- 
nism and functional significance of aberrant CD27 expres- 
sion on malignant B cells remains to be elucidated. 
Our findings with respect to the soluble form of CD27 
indicate that in patients with B-cell  malignancies, serum 
levels of sCD27 are correlated to disease activity cq tumor 
load. The lower sCD27 levels in intermediate-/high-grade 
NHL in comparison with CLL/low-grade NHL can be ex- 
plained both by the in general lower membrane expression 
of CD27 and the lower absolute tumor load. Although sug- 
gestive, the limited number of observations as well as the 
(in)frequency of serum sampling in our study do not yet 
allow for conclusions as to predictive value of sCD27 deter- 
minations. Our data strongly suggest that the sCD27 is de- 
rived from the malignant B cells. However, we  could not 
prove this because immunoprecipitation  studies did  not 
show differences between the sCD27 from the serum of the 
two patients tested (CLL and low-grade NHL) and a culture 
supernatant  of CD3-stimulated T lymphocytes (data not 
shown). Hence, the increased sCD27 levels could reflect T- 
cell activation as has been shown during acute cytomegalovi- 
rus and human immunodeficiency virus infections, in syno- 
vial fluid of RA patients and in the cerebrospinal fluid of 
multiple  sclerosis  patient^.^.^^^^^^  There  are  several argu- 
ments against this possibility. First, the sCD27 levels in pa- 
tients with B-cell malignancies are not only much higher 
than those reported in the patients with acute or chronic 
T-cell a~tivation,~",~,~'  but they also correlated with disease 
stage, as illustrated for CLL in Fig 5. Secondly, the splenec- 
tomy of a patient with a splenic NHL resulted in a rapid and 
permanent  decrease  in  sCD27.  Finally,  production  of 
sCD27 could be shown in the culture supernatant of puri- 
fied CLL-B cells (<  1  % CD3+ cells; data not shown). 
The mechanism of the generation of sCD27 by the malig- 
nant B cells is not yet known. Studies in T cells have indi- 
cated that membrane-bound and soluble CD27 have a com- 
mon  mRNA  and  protein  precursor, and that sCD27 is 
generated from the membrane-bound CD27 by  proteoly- 
s~s.~~  This process is strongly enhanced by T-cell activation. 
In vitro studies with B cells have shown that activation of 
CD27- B cells by staphylococcus aureus Cowan (SAC) and 
interleukin-2 can induce expression of membrane bound 
CD27.3  Under these conditions these B cells release soluble 
CD27 (R.Q.H., unpublished observations).  However, in ma- 
lignant B cells regulation of membrane expression and re- 
lease of CD27 might be different from that in normal T and 
B cells. This is suggested by  our unpublished observations 
that purified CLL-B cells, cultured for 4 days without any 
stimulation, release sCD27 into the supernatant. Neither 
this release  nor membrane expression of CD27 were  in- 
fluenced by  addition  of PMA and TNF, a combination 
shown to induce strong proliferation of CLL cells.33 
If membrane-bound CD27 is involved in the functional 
activity of the CD27+  T and B lymphocytes, the presence of 
high amounts of soluble  CD27 in the plasma might interfere 
with these functions. It would be interesting to investigate 
whether sCD27 contributes to the impaired cellular and hu- 
moral immunity and autoimmune phenomena frequently 
observed within this group of patients. 
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